Measles is an illness that can cause a rimed rash and fever which consequently leads to complications such as pneumonia, encephalitis, or even malnutrition. These effects stated are common to developing nations. My corporation is currently leading all other competitors in providing robust development services for measles vaccine and therapeutics encompassing all the existing subdomains for it.
Introduction to Measles
In the first instance, it is necessary to understand that the measles virus is part of the paramyxovidavae family. It is an extremely contagious viral illness. Before the 1960's after the invention of measles vaccine, the disease was responsible for over one million deaths each year around the globe. Due to immunization, some control has been gained, but the battle against it is far from over.
The transfer of Measles is through droplets and inhulation where it infects the respiratory tract and lymphoid tissue. Symptoms tend to start after an incubation period of around 10-12 days. Typical measles symptoms are red rashes, sore throat, cough, fever as well as nausea. It's important to note that the measles virus alters the immune system, causing hampered response long-term. In fact, years later, these changes can lead to many secondary diseases.
Fig.1 Target site mapping of the measles virus (MeV) polymerase inhibitor ERDRP-0519. (Plemper R. K., et al., 2020)
Vaccine Development for Measles
Live Attenuated Vaccines
Live Attenuated Vaccines: Various Moraten, Schwarz, and Edmonston-Zagreb vaccines have achieved excellent clinical eifficacy following regimented two-dose vaccinations. The initial Edmonston strain, from which these vaccines are derived, underwent a secondary attenuation via cell cultures passage and thus, provides moderate protection against measles.
Inactivated Vaccines
Inactivated Vaccines: Historically-used inactivated measles vaccinations were ineffective in the long-term due to the possibility of enhancement of disease upon subsequent infections of the wild type virus. Because of this benefit-risk scenario, the modern immunization program relies on the use of live attenuated vaccaines.
Novel Vaccines
Novel Vaccines: Advances in biotechnology have led to the emergence of new vaccine strategies such as those that utilize recombinant vector vaccines. In these vectored vaccines, the MeV antigens are incorporated into a non-pathogenic virus. The newly developed nucleic acid based vaccines (DNA, mRNA) allow an immune response against viral proteins without the use of live viruses.
Therapeutics Development for Measles
- Antiviral Therapeutics
Due to the limited number of cellular receptors that the virus uses, the development of antiviral drugs for measles is quite difficult. Not to mention, the high speed at which the virus replicates. Despite this challenge, work is currently underway to find compounds that can inhibit major fusion processes and viral polymerase. Such compounds include ERDRP-0519, which is a polymerase inhibitor and has shown potential in preclinical models.
- Immunotherapies
The immune response of measles patients may further be enhanced through the administration of immunoglobulins in conjunction with interferons. With the use of these therapies, the aim is to assist the immune system of the host to eliminate the virus and reduce any potential complications.
To get more information concerning our comprehensive services regarding measles therapeutic and vaccine development, we encourage you to follow the link provided.
Our Services
At our firm, we are glad to inform you that we possess a full range of services to assist you in the creation of unique measles vaccines and therapies. Our services are integrated on different levels for all phases of drug and vaccine development, from early research to later stage preclinical testing.
Preclinical Research
- Pharmacodynamics Study Services
- Pharmacokinetics Study Services
- Drug Safety Evaluation Services
Disease Models
- Cotton Rat (Sigmodon hispidus) Natural Susceptibility Models to Measles Virus
- Genomic CD46 Transgenic Animal Models
- CD150 (SLAM) Transgenic Mouse Models
With our depth of expertise and state-of-the-art facilities, our company is uniquely positioned to accelerate the development of next-generation measles vaccines and therapies. If you are interested in our services, please feel free to
contact us.
References
- Plemper, Richard K. "Measles resurgence and drug development." Current opinion in virology 41 (2020): 8-17.
- Griffin, Diane E. "Measles vaccine." Viral immunology 31.2 (2018): 86-95.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
